A Retrospective Study Investigating the Response to Crizotinib in Patients of Advanced Non–Small-Cell Lung Cancer (NSCLC) with ALK Rearrangements Detected by RT-PCR.
Phase of Trial: Phase IV
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2017 New trial record